Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 67

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 67
---
 seek to enter into collaborations, licenses and other similar arrangements 
 and may not be successful in doing so, and we may not realize the benefits of such relationships.             |

| • |     | If the custodians or authorized users of our controlling non-tangible                                                                                                                      
 assets, including chops and seals, fail to fulfill their responsibilities, or misappropriate or misuse these assets, our business and operations may be materially and adversely affected. |

Risks Related to Commercialization of Our Product Candidates

| • |     | Even if our Product Candidates receive regulatory approval, they will be subject to ongoing regulatory review 
 and significant post-marketing regulatory requirements and oversight.                                         |

| • |     | The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability. |

| • |     | The commercial success of our Product Candidates will depend upon the degree of market acceptance of such 
 Product Candidates by physicians, patients, healthcare payors and others in the medical community.        |

| • |     | The successful commercialization of our Product Candidates, if approved, will depend in part on the extent to                                                                                                                                             
 which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market 
 those products and decrease our ability to generate revenue.                                                                                                                                                                                              |

| • |     | We face significant competition, and if our competitors develop technologies or Product Candidates more                                                
 rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected. |

| • |     | If the market opportunities for our products are smaller than we believe they are, our revenue may be 
 adversely affected, and our business may suffer.                                                      |

5

| • |     | We currently have no marketing and sales organization and have no experience as a company in commercializing                                                                                                                                            
 products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able 
 to generate product revenue.                                                                                                                                                                                                                            |

| • |     | Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject 
 to additional regulatory burdens and other risks and uncertainties.                                            |

Risks Related to Our Business Operations